A detailed history of Frontier Capital Management CO LLC transactions in Novo Cure LTD stock. As of the latest transaction made, Frontier Capital Management CO LLC holds 871,420 shares of NVCR stock, worth $26.8 Million. This represents 0.14% of its overall portfolio holdings.

Number of Shares
871,420
Previous 1,028,331 15.26%
Holding current value
$26.8 Million
Previous $17.6 Million 22.68%
% of portfolio
0.14%
Previous 0.18%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$15.61 - $23.34 $2.45 Million - $3.66 Million
-156,911 Reduced 15.26%
871,420 $13.6 Million
Q2 2024

Aug 14, 2024

BUY
$11.83 - $24.05 $1.27 Million - $2.58 Million
107,215 Added 11.64%
1,028,331 $17.6 Million
Q1 2024

May 15, 2024

BUY
$12.42 - $17.29 $1.59 Million - $2.21 Million
127,642 Added 16.09%
921,116 $14.4 Million
Q4 2023

Feb 14, 2024

BUY
$11.13 - $15.78 $4.11 Million - $5.82 Million
369,037 Added 86.95%
793,474 $11.8 Million
Q3 2023

Nov 14, 2023

BUY
$16.15 - $42.35 $3.68 Million - $9.65 Million
227,942 Added 116.0%
424,437 $6.85 Million
Q2 2023

Aug 14, 2023

SELL
$40.29 - $82.51 $5.02 Million - $10.3 Million
-124,476 Reduced 38.78%
196,495 $8.15 Million
Q1 2023

May 15, 2023

SELL
$56.44 - $118.81 $1.2 Million - $2.52 Million
-21,239 Reduced 6.21%
320,971 $19.3 Million
Q4 2022

Feb 14, 2023

SELL
$63.98 - $85.37 $515,742 - $688,167
-8,061 Reduced 2.3%
342,210 $25.1 Million
Q3 2022

Nov 14, 2022

SELL
$67.99 - $89.57 $336,074 - $442,744
-4,943 Reduced 1.39%
350,271 $26.6 Million
Q2 2022

Jul 20, 2022

SELL
$56.6 - $89.9 $8.44 Million - $13.4 Million
-149,140 Reduced 29.57%
355,214 $24.7 Million
Q1 2022

Apr 14, 2022

BUY
$60.15 - $84.52 $4.27 Million - $6.01 Million
71,070 Added 16.4%
504,354 $41.8 Million
Q4 2021

Jan 19, 2022

BUY
$75.08 - $121.99 $15.5 Million - $25.2 Million
206,517 Added 91.07%
433,284 $32.5 Million
Q3 2021

Oct 19, 2021

SELL
$116.17 - $194.55 $15.4 Million - $25.8 Million
-132,499 Reduced 36.88%
226,767 $26.3 Million
Q2 2021

Aug 09, 2021

BUY
$130.4 - $225.58 $46.5 Million - $80.4 Million
356,364 Added 12279.94%
359,266 $79.7 Million
Q1 2021

May 13, 2021

BUY
$124.11 - $190.17 $360,167 - $551,873
2,902 New
2,902 $384,000
Q4 2020

Jan 19, 2021

SELL
$112.16 - $174.14 $16.9 Million - $26.2 Million
-150,350 Closed
0 $0
Q3 2020

Nov 16, 2020

BUY
$58.05 - $111.31 $7.5 Million - $14.4 Million
129,123 Added 608.3%
150,350 $16.7 Million
Q2 2020

Jul 17, 2020

SELL
$57.2 - $74.41 $8.58 Million - $11.2 Million
-150,031 Reduced 87.61%
21,227 $1.26 Million
Q1 2020

Apr 16, 2020

BUY
$57.05 - $95.75 $7.54 Million - $12.7 Million
132,202 Added 338.49%
171,258 $11.5 Million
Q4 2019

Feb 14, 2020

SELL
$68.3 - $93.8 $815,433 - $1.12 Million
-11,939 Reduced 23.41%
39,056 $3.29 Million
Q3 2019

Nov 14, 2019

SELL
$61.86 - $97.8 $22 Million - $34.8 Million
-355,838 Reduced 87.47%
50,995 $3.81 Million
Q2 2019

Aug 14, 2019

BUY
$42.22 - $63.23 $1.72 Million - $2.58 Million
40,823 Added 11.15%
406,833 $25.7 Million
Q1 2019

May 07, 2019

BUY
$31.96 - $56.12 $648,276 - $1.14 Million
20,284 Added 5.87%
366,010 $17.6 Million
Q4 2018

Jan 25, 2019

BUY
$28.72 - $52.63 $7 Million - $12.8 Million
243,903 Added 239.54%
345,726 $11.6 Million
Q3 2018

Oct 30, 2018

SELL
$32.0 - $52.4 $8.13 Million - $13.3 Million
-254,144 Reduced 71.4%
101,823 $5.34 Million
Q2 2018

Aug 03, 2018

SELL
$19.85 - $32.0 $14.9 Million - $24.1 Million
-751,932 Reduced 67.87%
355,967 $11.1 Million
Q1 2018

Apr 30, 2018

BUY
$19.3 - $23.65 $501,819 - $614,923
26,001 Added 2.4%
1,107,899 $24.2 Million
Q4 2017

Jan 18, 2018

BUY
$16.3 - $21.9 $4.05 Million - $5.44 Million
248,322 Added 29.79%
1,081,898 $21.9 Million
Q3 2017

Oct 31, 2017

BUY
$18.05 - $21.75 $15 Million - $18.1 Million
833,576
833,576 $16.5 Million

Others Institutions Holding NVCR

About NovoCure Ltd


  • Ticker NVCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Instruments & Supplies
  • Shares Outstandng 104,950,000
  • Market Cap $3.23B
  • Description
  • NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...
More about NVCR
Track This Portfolio

Track Frontier Capital Management CO LLC Portfolio

Follow Frontier Capital Management CO LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Frontier Capital Management CO LLC, based on Form 13F filings with the SEC.

News

Stay updated on Frontier Capital Management CO LLC with notifications on news.